Plasminogen activator inhibitor-1 4G/5G polymorphism and retinopathy risk in type 2 diabetes: a meta-analysis

BackgroundMounting evidence has suggested that plasminogen activator inhibitor-1 (PAI-1) is a candidate for increased risk of diabetic retinopathy. Studies have reported that insertion/deletion polymorphism in the PAI-1 gene may influence the risk of this disease. To comprehensively address this issue, we performed a meta-analysis to evaluate the association of PAI-1 4G/5G polymorphism with diabetic retinopathy in type 2 diabetes.MethodsData were retrieved in a systematic manner and analyzed using Review Manager and STATA Statistical Software. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of associations.ResultsNine studies with 1, 217 cases and 1, 459 controls were included. Allelic and genotypic comparisons between cases and controls were evaluated. Overall analysis suggests a marginal association of the 4G/5G polymorphism with diabetic retinopathy (for 4G versus 5G: OR 1.13, 95%CI 1.01 to 1.26; for 4G/4G versus 5G/5G: OR 1.30, 95%CI 1.04 to 1.64; for 4G/4G versus 5G/5G + 4G/5G: OR 1.26, 95%CI 1.05 to 1.52). In subgroup analysis by ethnicity, we found an association among the Caucasian population (for 4G versus 5G: OR 1.14, 95% CI 1.00 to 1.30; for 4G/4G versus 5G/5G: OR 1.33, 95%CI 1.02 to 1.74; for 4G/4G versus 5G/5G + 4G/5G: OR 1.41, 95%CI 1.13 to 1.77). When stratified by the average duration of diabetes, patients with diabetes histories longer than 10 years have an elevated susceptibility to diabetic retinopathy than those with shorter histories (for 4G/4G versus 5G/5G: OR 1.47, 95%CI 1.08 to 2.00). We also detected a higher risk in hospital-based studies (for 4G/4G versus 5G/5G+4G/5G: OR 1.27, 95%CI 1.02 to 1.57).ConclusionsThe present meta-analysis suggested that 4G/5G polymorphism in the PAI-1 gene potentially increased the risk of diabetic retinopathy in type 2 diabetes and showed a discrepancy in different ethnicities. A higher susceptibility in patients with longer duration of diabetes (more than 10 years) indicated a gene-environment interaction in determining the risk of diabetic retinopathy.

[1]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[2]  R. Klein,et al.  Identification of Diabetic Retinopathy Genes through a Genome-Wide Association Study among Mexican-Americans from Starr County, Texas , 2010, Journal of ophthalmology.

[3]  Thomas A Trikalinos,et al.  Genetic associations in large versus small studies: an empirical assessment , 2003, The Lancet.

[4]  A. Hamsten,et al.  Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[5]  T. Saruta,et al.  Paraoxonase 1 Gln/Arg polymorphism is associated with the risk of microangiopathy in Type 2 diabetes mellitus. , 2004, Diabetic medicine : a journal of the British Diabetic Association.

[6]  F. Tsai,et al.  Genome-wide association study of diabetic retinopathy in a Taiwanese population. , 2011, Ophthalmology.

[7]  N. Ashton.  Vascular basement membrane changes in diabetic retinopathy. Montgomery lecture, 1973. , 1974, The British journal of ophthalmology.

[8]  D. Ray,et al.  VEGF polymorphisms are associated with severity of diabetic retinopathy. , 2008, Investigative ophthalmology & visual science.

[9]  T. Ogihara,et al.  Meta-analysis of association of insertion/deletion polymorphism of angiotensin I-converting enzyme gene with diabetic nephropathy and retinopathy , 1998, Diabetologia.

[10]  D. Petrovič,et al.  Manganese Superoxide Dismutase Gene Polymorphism (V16A) is Associated with Diabetic Retinopathy in Slovene (Caucasians) Type 2 Diabetes Patients , 2007, Disease markers.

[11]  J. Schölmerich,et al.  Allelic Frequency of the PAI‐1 4G/5G Promoter Polymorphism in Patients with Type 2 Diabetes Mellitus and Lack of Association with PAI‐1 Plasma Levels , 2004, Endocrine Research.

[12]  T. Mahjoub,et al.  Diabetic retinopathy, PAI-1 4G/5G and -844G/A polymorphisms, and changes in circulating PAI-1 levels in Tunisian type 2 diabetes patients. , 2009, Diabetes & metabolism.

[13]  T. Saruta,et al.  Paraoxonase 1 192Gln/Arg polymorphism is associated with the risk of microangiopathy in Type 2 diabetes mellitus , 2004 .

[14]  W. Niu,et al.  An updated meta-analysis of methylenetetrahydrofolate reductase gene 677C/T polymorphism with diabetic nephropathy and diabetic retinopathy. , 2012, Diabetes research and clinical practice.

[15]  Shi-qun Liu,et al.  [Relationship between plasminogen activator inhibitor-1 gene 4G/5G polymorphism and type 2 diabetic nephropathy in Chinese Han patients in Guangdong Province]. , 2004, Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA.

[16]  Diabetic retinopathy in Euro-Brazilian type 2 diabetic patients: relationship with polymorphisms in the aldose reductase, the plasminogen activator inhibitor-1 and the methylenetetrahydrofolate reductase genes. , 2003, Diabetes research and clinical practice.

[17]  T. Zhao,et al.  Association between the -634C/G polymorphisms of the vascular endothelial growth factor and retinopathy in type 2 diabetes: a meta-analysis. , 2010, Diabetes research and clinical practice.

[18]  C. Hanis,et al.  Genetics of diabetic retinopathy , 2006, Current diabetes reports.

[19]  M. Grant,et al.  Plasminogen activator inhibitor (PAI)-1 overexpression in retinal microvessels of PAI-1 transgenic mice. , 2000, Investigative ophthalmology & visual science.

[20]  J. Hirschhorn,et al.  A comprehensive review of genetic association studies , 2002, Genetics in Medicine.

[21]  P. Grant,et al.  Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy. , 2001, Diabetes.

[22]  P. Bennett,et al.  Diabetes incidence and prevalence in Pima Indians: a 19-fold greater incidence than in Rochester, Minnesota. , 1978, American journal of epidemiology.

[23]  B. Peterlin,et al.  Insertion/Deletion Plasminogen Activator Inhibitor 1 and Insertion/Deletion Angiotensin-Converting Enzyme Gene Polymorphisms in Diabetic Retinopathy in Type 2 Diabetes , 2003, Ophthalmologica.

[24]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.

[25]  C. Longui,et al.  Evaluation of AC(n) and C(-106)T polymorphisms of the aldose reductase gene in Brazilian patients with DM1 and susceptibility to diabetic retinopathy , 2007, Molecular vision.

[26]  J. Chan,et al.  Association of plasminogen activator inhibitor-1 4G/4G genotype and type 2 diabetic nephropathy in Chinese patients. , 2000, Kidney international.

[27]  D. Petrovič,et al.  The 4a/4a genotype of the VNTR polymorphism for endothelial nitric oxide synthase (eNOS) gene predicts risk for proliferative diabetic retinopathy in Slovenian patients (Caucasians) with type 2 diabetes mellitus , 2012, Molecular Biology Reports.

[28]  W. Knowler,et al.  Diabetic Retinopathy, Promoter (4G/5G) Polymorphism of PAI-1 Gene, and PAI-1 Activity in Pima Indians With Type 2 Diabetes , 1997, Diabetes Care.

[29]  C. Begg,et al.  Operating characteristics of a rank correlation test for publication bias. , 1994, Biometrics.

[30]  J. Ioannidis,et al.  Quantitative Synthesis in Systematic Reviews , 1997, Annals of Internal Medicine.

[31]  Jinkui Yang,et al.  Angiotensin-converting enzyme gene polymorphism is associated with proliferative diabetic retinopathy: a meta-analysis , 2010, Acta Diabetologica.

[32]  I. Stefanidis,et al.  The relationship between C677T methylenetetrahydrofolate reductase gene polymorphism and retinopathy in type 2 diabetes: a meta-analysis , 2005, Journal of Human Genetics.

[33]  S. Nonen,et al.  MTHFR gene polymorphism as a risk factor for diabetic retinopathy in type 2 diabetic patients without serum creatinine elevation. , 2003, Diabetes care.

[34]  J. C. Huber,et al.  Familial aggregation of severity of diabetic retinopathy in Mexican Americans from Starr County, Texas. , 2005, Diabetes care.

[35]  R. Klein,et al.  The Role of Genetics in Susceptibility to Diabetic Retinopathy , 2009, International ophthalmology clinics.

[36]  M. Margaglione,et al.  PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis: relation to environmental and genetic determinants. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[37]  B. Binder,et al.  The 4G/5G Sequence Polymorphism in the Promoter of Plasminogen Activator Inhibitor-1 (PAI-1) Gene: Relationship to Plasma PAI-1 Level in Venous Thromboembolism , 1998, Thrombosis and Haemostasis.

[38]  G. Siest,et al.  Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: a family study with part of the Stanislas Cohort. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[39]  C. Gutiérrez,et al.  Genetic Variation in Promoter (4G/5G) of Plasminogen Activator Inhibitor 1 Gene in Type 2 Diabetes: Absence of relationship with microangiopathy , 1998, Diabetes Care.

[40]  E. Schadt.  Molecular networks as sensors and drivers of common human diseases , 2009, Nature.

[41]  Deborah Doniach,et al.  Islet cell antibodies and diabetes mellitus in Pima Indians , 1979, Diabetologia.

[42]  V. Wiwanitkit.  Angiotensin-converting enzyme gene polymorphism is correlated to diabetic retinopathy: a meta-analysis. , 2008, Journal of diabetes and its complications.

[43]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[44]  M. Daly,et al.  Candidate gene association study for diabetic retinopathy in persons with type 2 diabetes: the Candidate gene Association Resource (CARe). , 2011, Investigative ophthalmology & visual science.